Covaxin: The best vaccine you can’t get

Recently published results of the phase 3 clinical trial for Covaxin shows that it is 93% effective in preventing serious disease.

The recently published results of the phase 3 clinical trial for the Covid-19 candidate vaccine, Covaxin, are an astounding blessing for the world — a world in which more people have died from Covid in the first half of 2021 than in all of 2020, with the most dangerous variants so far ravaging the large swaths of humanity where vaccination rates are mostly less than 1%.

Covaxin’s now fully demonstrated efficacy, and it’s basis on time tested manufacturing processes, used for decades for routine childhood vaccines like polio, means it is the best tool to address the hesitancy of millions of Americans with respect to the MNRA vaccines and a potentially crucial tool for the mass immunization of humanity, outside the few already highly vaccinated countries. That is, in turn, the best protection the already vaccinated can have from the potential emergence of new variants which could continue to erode, or even fully escape from, the protection currently offered by the MRNA vaccines.

Also, because of its basis on the same platform historically used to manufacture childhood vaccines, Covaxin is also likely to prove to be the answer to how to vaccinate America’s younger children, many millions of who are still today being deprived of normal social interactions and prevented, behind masks, from seeing the smiles of their friends.

Leave a Comment